Background. Bleeding is associated with viral hemorrhagic fevers; however, thromboembolic complications have received less attention. Hemorrhagic fever with renal syndrome (HFRS) is a mild viral hemorrhagic fever caused by Puumala hantavirus. We previously identified HFRS as a risk factor for myocardial infarction and stroke, but the risk for venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is unknown.
Viral hemorrhagic fever contains members from 4 viral families: Bunyaviridae, Filoviridae, Arenaviridae, and Flaviviridae. Pathogenic hantaviruses from the Bunyaviridae family cause hantavirus cardiopulmonary syndrome in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Eurasia, and recently hantaviruses have also been reported from Africa [1] . Annually, >100 000 cases of hantavirus infection are estimated to be diagnosed worldwide [1] . Puumala hantavirus causes HFRS and is a mild viral hemorrhagic fever endemic in Central and Northern Europe [2] . HFRS is a disease characterized by endothelial and platelet activation, coagulation disturbances, and renal dysfunction [1, [3] [4] [5] [6] .
Endothelial dysfunction and hypercoagulability are common during viral hemorrhagic fever and are risk factors for thromboembolism [2, 7, 8] . Recently, HFRS was identified as a risk factor for the arterial thromboembolic events: acute myocardial infarction (AMI) and stroke [9] . However, no studies have focused on the risk for venous thromboembolism (VTE) following a viral hemorrhagic fever. Therefore, the present study determined the risk of VTE occurrence in a large cohort of patients with HFRS.
METHODS

Subject and Data Sources
HFRS is a notifiable disease in Sweden; therefore, the Public Health Agency of Sweden registers all HFRS-diagnosed individuals by their personal identity number (PIN). Every Swedish citizen is issued a PIN at birth by the Swedish Tax Agency. The diagnosis of HFRS is confirmed by detection of specific immunoglobulin M (IgM) and/or immunoglobulin G (IgG) seroconversion using an indirect immunofluorescence method or enzyme-linked immunosorbent assay in accredited laboratories, as previously described [9] . The data reported into the HFRS database include dates of HFRS onset, sample date, diagnosis, and reporting as previously reported by our group [9] . Data on venous thromboembolism (VTE) and date of HFRS onset were obtained by cross-linking the HFRS database with the inpatient register (IPR), Cause of Death Register, and Outpatient Register using the PIN for each patient. All data were anonymized by the Swedish National Board of Health and Welfare. 
Study Design and Statistical Analysis
The incidence rate ratio (IRR) and 95% confidence interval (CI) of venous and/or arterial thromboembolism during risk periods following HFRS onset compared with control periods were determined using the self-controlled case series method. The risk period was divided into weeks following HFRS disease onset: 1-2, 3-4, 5-8, 9-12, 13-26, and 27-52 weeks (or, for follow-up studies: 1-4, 5-8, 9-12, and 13-52 weeks). Exposure to the virus is unlikely in the immediate time period following VTE due to hospitalization and recovery. In addition, HFRS diagnosis may be delayed [9] . We therefore excluded the 26 weeks prior to HFRS disease onset to allow for these factors. The control period spanned the period 1 January 1998 until 31 December 2013 or date of death, excluding the 26-week preexposure buffer period and the risk period (Figure 1 ). Patients with VTE as the cause of death at the time of event were excluded to meet the assumptions of the self-controlled case series method [10] .
All models were adjusted for age using the age groups 0-49, 50-59, 60-69, 70-79, and ≥80 years of age at thromboembolism event, as the incidence of VTE increases with age [11, 12] . A likelihood ratio test was applied to examine the interactions between sex or seasonality and VTE risk following HFRS onset. Seasons were divided into colder months (October through March) and warmer months (April through September). Median ages were compared using nonparametric MannWhitney test. Sex distribution was compared using χ 2 test.
Sensitivity analyses were run excluding individuals with other known risk factors for VTE: cancer, surgery, or hospitalization for any reason 6 weeks prior to the event, and the age-adjusted IRR for VTE following HFRS was calculated separately [11, 12] . The cancer diagnoses codes were as follows: ICD-7 codes 140-239; ICD-8 codes 140-239; ICD-9 codes 140-239; and ICD-10 codes C00-D48. Two separate analyses were performed where individuals diagnosed with cancer were excluded. The first analysis excluded individuals with diagnosis of cancer at any time point of their life regardless when the VTE occurred. The second analysis excluded only individuals with a cancer diagnosis within ±12 months of VTE event.
We analyzed whether the length of hospitalization differed between the control period (including buffer period) and the risk period, thereby predisposing to VTE, using the nonparametric Mann-Whitney U test. Because anticoagulation treatment indicates other risk factors and affects the coagulation system, individuals on anticoagulation therapy prior to event were excluded in a follow-up analysis and the IRR for VTE following HFRS calculated. These patients were identified using the ICD-10 code Z921 (long-term usage of anticoagulants in personal history); anatomical therapeutic chemical code: B01AA03 (warfarin) or B01AB04 (fragmin); and atrial fibrillation or heart valve prosthesis of nonbiological origin (ICD-7: 433.12 and 433.13; ICD-8: 427.92 and 427.90; ICD-9: 427D, 427A, and V43D; and ICD-10: I48 or Z952).
Statistical analyses of date were performed using SPSS (version 24) or Stata (version 12.0 SE) software. All P values are 2-sided and P < .05 was considered statistically significant.
RESULTS
From 1997, when HFRS became a notifiable disease, there were a total of 7244 patients registered in the HFRS database up to 2014. From these patients who were diagnosed with HFRS from 1997, 6435 (88.8%) were hospitalized for any cause during 1964-2013 (IPR). A total of 2663 (36.8%) were hospitalized due to HFRS (IPR) either as the main or contributing cause of hospitalization. Four hundred eighty-three (6.7%) had died during 1997-2013 (Cause of Death register). During 1998 to 2013, there were 146 HFRS patients with a first VTE (2%). Of these, 34 patients (23%) had their first VTE during our specified risk period (0-52 weeks following HFRS onset). The baseline demographics and the number of individuals with known risk factors for VTE are shown in Table 1 . Generally, the individuals in the study groups were older compared with the HFRS cohort. In addition, the sex distribution differed significantly between the PE study group compared with the HFRS cohort ( Table 1) .
Venous Thromboembolism Following Hemorrhagic Fever With Renal Syndrome Onset
The IRR for a first VTE was significantly increased in the first half year (apart from 9-12 weeks) following HFRS (Table 2 ) compared with the control period. VTE was further divided into DVT and PE, where the IRR for DVT was significantly increased the first year following HFRS. The IRR for PE was significantly higher in the first month only following HFRS. The IRR for PE in the first 2 weeks following HFRS was higher than that for DVT. Sex had a significant modifying effect on the association between HFRS and VTE (Supplementary Table 2 ). The IRR for VTE for females was higher compared with males in the 4 weeks following HFRS onset. Similarly, the risks for DVT and PE were higher in females compared with males in the same time period (Table 3) . Season did not have a confounding effect on VTE (Supplementary Table  2 ). Other risk factors for VTE include cancer diagnosis, surgery, and immobilization [11, 12] . However, the association between HFRS and VTE was still significant even after excluding individuals who had had a cancer diagnosis at (1) any time point during the observation period or (2) within ±12 months of HFRS (Supplementary Table 3 ). The association between HFRS and VTE was still significant even after excluding individuals who had undergone surgery or were hospitalized for any reason 6 weeks prior to HFRS, respectively (Supplementary Table 3 ). In addition, anticoagulation treatment could attenuate the association between HFRS and VTE. Yet, the association was similar even after these individuals were excluded (Supplementary Table 3 ). Another risk factor for VTE is immobilization. If patients are hospitalized for a longer time during HFRS (risk period) compared with hospitalizations during the control period, this could predispose to VTE [11, 12] . We did not find a significant difference in the length of hospitalization in the control period vs the risk period (Supplementary Table 4) .
DISCUSSION
This study of all Swedish HFRS patients from 1997 to 2014 shows an increased risk for VTE following a viral hemorrhagic fever. We previously identified HFRS as a risk factor for AMI and stroke [9] .
We found a statistically significant modifying effect of sex on the association between HFRS and VTE, with females having a higher IRR for a first VTE compared with males. Furthermore, although the IRRs for females were higher, the length of time with increased risk for VTEs following HFRS onset was longer in males. Only 1 female <59 years of age had VTE during the risk period, indicating that reproductive risk factors are not an explanation for our results. The cytokine profile differs between males and females during acute HFRS; whether this translates into an increased risk for VTE is unknown [13] . Other risk factors for VTE include cancer, surgery, and immobilization (hospitalization) [11, 14] and a protective factor is anticoagulants, though when we performed sensitivity analyses including these factors, they did not modify our results.
Previous studies have associated infections with increased risk for VTE [15] [16] [17] . In a study with a similar methodology to ours, the risk for a DVT and PE was increased approximately 2-fold in the first 2 weeks following a urinary tract infection and similarly for DVT following a systemic respiratory tract infection [15] . Notably, we observe in our study of HFRS patients a much higher risk for DVT (approximately 46-fold) and PE (approximately 73-fold) in the same period, indicating the potency of the interaction between hantaviral infection, the endothelium, and the coagulation system. Our results are further supported by autopsies of patients who died due to Puumala hantavirus infection, who had thromboses in pulmonary vessels [18] . That HFRS patients have coagulopathy is indicated by almost one-third of HFRS patients fulfilling criteria for disseminated intravascular coagulation [5] , increased platelet activation during HFRS [4] , and deregulated fibrinolysis [6] , and the identification of HFRS as a risk factor for the 2 specific cardiovascular events AMI and stroke [9] . Endothelial cells are a key player in VHF pathogenesis and clinical outcome [19] , and hantaviruses target endothelial cells during infection, resulting in increased coagulation and platelet adhesion [20] . Furthermore, the increased risk for arterial and venous thromboembolism during HFRS, as shown in our previous and current study, indicates that endothelial cells are affected during hantaviral infection regardless of their location [9] . Thereby, there are several mechanisms during hantavirus infection that could explain the increased risk for thromboembolism that we show in this cohort-based study.
Concerning other viral hemorrhagic fevers, case reports for dengue virus indicate a similar tendency for VTE that we observed in our study [21] . Also, thrombosis is relevant for the outcome in viral hemorrhagic fever, which was indicated in a study where increased von Willebrand factor levels in patients with hemorrhagic manifestations following infection with Sudan ebolavirus led to speculation that these patients have excessive thrombosis [22] . In addition, case reports of 2 other Ebola virus-infected patients indicated a hypercoagulable phase following infection that warranted treatment with low-molecular-weight heparin [23] . However, the risk for thromboembolism following these viral hemorrhagic fevers has yet to be determined and quantified.
A strength of our study is that it comprises all individuals in Sweden with verified HFRS since 1997 until 2014. In addition, we have data from the IPR since 1964, with complete coverage from 1987 [24] . We could therefore identify the first VTE event with high precision from 1987 up until 2013.
The self-controlled case series method requires precision of the exposure date (HFRS disease onset), as the method is sensitive to timing and dates [10] . For nearly 80% of our patients, we have the actual date of HFRS disease onset, which is another strength of our study. The least accurate date, the date of report to the Public Health Agency of Sweden, constitutes only 0.7% of the dates. However, to circumvent potential imprecision of HFRS disease onset, we included a 6-month buffer prior to the HFRS date. This ensures that a patient who receives a delayed HFRS diagnosis or registration date with VTE during that delay period will not affect the actual IRR for a thromboembolism.
A limitation of this study is that we do not have access to information regarding whether the individuals are on systemic hormone replacement therapy, use oral contraceptives, or are pregnant, as these are risk factors for VTE [11, 14] .
In Sweden, the IPR has been extensively validated concerning the codes for AMI and stroke diagnoses but not for VTE [24] . There is a potential risk for less accuracy and over-or underestimation of VTE events, which is a limitation of our study. However, that risk should equally apply to both the control period and the risk period. Thereby, the probability of it affecting the IRR following HFRS is likely low.
An additional limitation is that, although we did not find a significant difference in the length of hospitalization between the control periods compared to the risk period, the association between HFRS and VTE could still be mediated in part by immobility. Further in vivo studies are required to ascertain the link between HFRS and VTE.
We show a significant but transient association between VTE and HFRS. Previous studies show a reduction in VTE in patients with infectious disease who were treated with thromboprophylaxis [25] . The Wells score for DVT and PE do not include infectious diseases as a risk factor. A scoring system that takes infectious disease, among others, into account showed a reduction in VTE following identification of high-risk groups with subsequent thromboprophylaxis treatment [26] . Our study raises the question whether some patients with HFRS, and possibly other viral hemorrhagic fevers, could potentially benefit from similar thromboprophylaxis in the short-term period. Further clinical studies are warranted to support such recommendations.
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